Influenza treatment with oseltamivir outside of labeled recommendations

奥司他韦 医学 神经氨酸酶抑制剂 重症监护室 加药 神经氨酸酶 内科学 人口 随机对照试验 儿科 重症监护医学 病毒学 病毒 2019年冠状病毒病(COVID-19) 疾病 传染病(医学专业) 环境卫生
作者
Brianna M. McQuade,Melissa Blair
出处
期刊:American Journal of Health-system Pharmacy [Oxford University Press]
卷期号:72 (2): 112-116 被引量:24
标识
DOI:10.2146/ajhp140390
摘要

Published evidence regarding the use of the antiinfluenza agent oseltamivir outside of the standard dosing recommendations is reviewed.Oseltamivir is a neuraminidase inhibitor indicated for the treatment of uncomplicated influenza in patients two weeks of age or older who have been symptomatic for no more than two days; the recommended dosage is 75 mg twice daily by mouth for five days. A literature search identified six studies evaluating the effects of administering oseltamivir 48 hours or more after the onset of influenza symptoms, administering the drug at double the standard dose, or continuing therapy for more than five days. Two randomized controlled trials found that double-dose oseltamivir therapy conferred no significant survival benefit. The results of one retrospective study of intensive care unit (ICU) patients infected with the influenza H1N1 strain suggested improved survival among those who received oseltamivir no later than five days after symptom onset.Oseltamivir may increase survival when used within five days of symptom onset in influenza H1N1-infected patients who require ICU admission. There appears to be no benefit in starting treatment more than 48 hours after symptom onset in hospitalized general medicine patients or outpatients infected with either H1N1 or other influenza strains or in doubling the dose of oseltamivir in hospitalized patients or outpatients. There are scant data supporting the use of oseltamivir for longer than five days in any patient population, with the possible exception of critically ill H1N1-infected ICU patients, who may benefit from extended treatment in some cases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小马过河应助尼尼采纳,获得10
1秒前
1秒前
1秒前
吾将上下而求索完成签到,获得积分10
1秒前
1秒前
1秒前
科研通AI2S应助LIN采纳,获得10
2秒前
2秒前
2秒前
喜悦的半青完成签到,获得积分10
2秒前
3秒前
好宝宝发布了新的文献求助10
4秒前
上官若男应助程艳采纳,获得80
4秒前
伊可创发布了新的文献求助10
5秒前
Ava应助szh123采纳,获得10
6秒前
锦七发布了新的文献求助10
6秒前
小二郎应助收手吧大哥采纳,获得10
8秒前
9秒前
在水一方应助lm采纳,获得10
9秒前
可爱的函函应助jingjingA采纳,获得10
9秒前
Zdh同学完成签到,获得积分10
10秒前
我是老大应助淡然的铭采纳,获得10
11秒前
girl完成签到,获得积分10
12秒前
13秒前
华仔应助HAHAHA采纳,获得10
13秒前
13秒前
小坤同学发布了新的文献求助10
14秒前
15秒前
musejie应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
quhayley应助科研通管家采纳,获得10
15秒前
情怀应助科研通管家采纳,获得10
15秒前
Jasper应助科研通管家采纳,获得10
15秒前
15秒前
15秒前
英俊的铭应助科研通管家采纳,获得10
16秒前
星辰大海应助科研通管家采纳,获得10
16秒前
李爱国应助科研通管家采纳,获得10
16秒前
SYLH应助科研通管家采纳,获得10
16秒前
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988732
求助须知:如何正确求助?哪些是违规求助? 3531027
关于积分的说明 11252281
捐赠科研通 3269732
什么是DOI,文献DOI怎么找? 1804764
邀请新用户注册赠送积分活动 881869
科研通“疑难数据库(出版商)”最低求助积分说明 809021